### Client Billed - Molecular Tests

<table>
<thead>
<tr>
<th>Category</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Panels &amp; Profiles</td>
<td>1</td>
<td>HPV DNA Tissue Testing</td>
<td>87624</td>
<td>No</td>
</tr>
</tbody>
</table>

### Medicare Billed - Molecular Tests

<table>
<thead>
<tr>
<th>Category</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoARRAY®</td>
<td>1</td>
<td>NeoARRAY SNP/Cytogenetic Profile</td>
<td>No</td>
<td>81229</td>
</tr>
<tr>
<td>NeoLAB™</td>
<td>2</td>
<td>NeoLAB AML Profile - Liquid Biopsy¹</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>NeoLAB BTK Inhibitor Acquired Resistance Panel - Liquid Biopsy</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>NeoLAB EGFR T790M - Liquid Biopsy</td>
<td>No</td>
<td>81235</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>NeoLAB FLT3 Mutation Analysis - Liquid Biopsy²</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>NeoLAB IDH1 Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81120</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>NeoLAB IDH2 Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81121</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>NeoLAB inv(16), CBFB-MYH11 Translocation - Liquid Biopsy</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>NeoLAB KIT (c-KIT) Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81272</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>NeoLAB KRAS Mutation Analysis - Liquid Biopsy²</td>
<td>No</td>
<td>81275</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>NeoLAB MDS/CMMML Profile - Liquid Biopsy¹</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>NeoLAB Myeloid Disorders Profile - Liquid Biopsy¹</td>
<td>No</td>
<td>81455</td>
</tr>
<tr>
<td></td>
<td>13</td>
<td>NeoLAB NPM1 Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81310</td>
</tr>
<tr>
<td></td>
<td>14</td>
<td>NeoLAB NRAS Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81311</td>
</tr>
<tr>
<td></td>
<td>15</td>
<td>NeoLAB PML-RARA Translocation, t(15;17) - Liquid Biopsy</td>
<td>No</td>
<td>81315</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>NeoLAB Prostate - Liquid Biopsy</td>
<td>No</td>
<td>0011M</td>
</tr>
<tr>
<td></td>
<td>17</td>
<td>NeoLAB RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8,21) - Liquid Biopsy</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>NeoLAB Solid Tumor Monitor - Liquid Biopsy</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td>NeoTYPE®</td>
<td>19</td>
<td>NeoTYPE AML Prognostic Profile¹</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>NeoTYPE AITL/Peripheral T-Cell Lymphoma Profile¹</td>
<td>No</td>
<td>81479</td>
</tr>
</tbody>
</table>

¹ CPT Code G0452 is not billed in NeoTYPE, NeoLAB
² CPT code(s) updated - See "List of tests with updated CPT code(s)"

**Note:** Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients.

The CPT codes provided here are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
# Out-Patient Billing CPT Codes

## Updated Date: August 13, 2018

Note: Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients.

The CPT codes provided here are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

## Medicare Billed - Molecular Tests (Continued)

<table>
<thead>
<tr>
<th>Category</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NeoTYPE</strong></td>
<td>21</td>
<td>NeoTYPE AML Favorable-Risk Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>NeoTYPE Brain Tumor Profile[^2]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>23</td>
<td>NeoTYPE Breast Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>NeoTYPE Cervical Tumor Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>NeoTYPE CLL Prognostic Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>26</td>
<td>NeoTYPE Colorectal Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>27</td>
<td>NeoTYPE Discovery Profile for Solid Tumors[^1]</td>
<td>No</td>
<td>81455</td>
</tr>
<tr>
<td></td>
<td>28</td>
<td>NeoTYPE Endometrial Tumor Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>NeoTYPE Esophageal Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>30</td>
<td>NeoTYPE Gastric Tumor Profile</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>31</td>
<td>NeoTYPE GI Predictive Profile[^2]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>NeoTYPE GIST Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>33</td>
<td>NeoTYPE Head &amp; Neck Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>34</td>
<td>NeoTYPE JMML Profile[^1]</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>35</td>
<td>NeoTYPE Liposarcoma Fusion Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>36</td>
<td>NeoTYPE Liver/Biliary Tumor Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>37</td>
<td>NeoTYPE Lung Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>38</td>
<td>NeoTYPE Lymphoma Profile[^1]</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>39</td>
<td>NeoTYPE MDS/CMML Profile[^1]</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>NeoTYPE Melanoma Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>41</td>
<td>NeoTYPE MPN Profile[^1]</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>42</td>
<td>NeoTYPE Myeloid Disorders Profile[^1]</td>
<td>No</td>
<td>81455</td>
</tr>
<tr>
<td></td>
<td>43</td>
<td>NeoTYPE Other Solid Tumor Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>44</td>
<td>NeoTYPE Ovarian Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>45</td>
<td>NeoTYPE Pancreas Tumor Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>46</td>
<td>NeoTYPE Precision Profile for Solid Tumors[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>47</td>
<td>NeoTYPE Soft Tissue Tumor Profile[^1]</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>NeoTYPE Thyroid Profile[^1]</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td><strong>Other Panels &amp; Profiles</strong></td>
<td>49</td>
<td>BRCA1 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81214</td>
</tr>
<tr>
<td></td>
<td>50</td>
<td>BRCA1/2 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81162</td>
</tr>
<tr>
<td></td>
<td>51</td>
<td>Hereditary Cancer Comprehensive Panel</td>
<td>No</td>
<td>81432</td>
</tr>
<tr>
<td></td>
<td>52</td>
<td>Hereditary Cancer Susceptibility for Pediatrics</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>53</td>
<td>Hereditary DNA Repair Panel for Prostate Cancer</td>
<td>No</td>
<td>81445</td>
</tr>
</tbody>
</table>

[^1]: CPT Code G0452 is not billed in NeoTYPE, NeoLAB  
[^2]: CPT code(s) updated - See “List of tests with updated CPT code(s)"

Note: Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients.
Medicare Billed - Molecular Tests (Continued)

<table>
<thead>
<tr>
<th>Category &amp; Profiles</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Panels &amp; Profiles</td>
<td>54</td>
<td>Lynch Syndrome</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td></td>
<td>55</td>
<td>ABL1 Kinase Domain Mutation Analysis</td>
<td>No</td>
<td>81170</td>
</tr>
<tr>
<td></td>
<td>56</td>
<td>ALK Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>57</td>
<td>Androgen Receptor Mutation Analysis</td>
<td>No</td>
<td>81405</td>
</tr>
<tr>
<td></td>
<td>58</td>
<td>ASXL1 Mutation Analysis</td>
<td>No</td>
<td>81175</td>
</tr>
<tr>
<td></td>
<td>59</td>
<td>ATRX Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>B-Cell Gene Rearrangement²</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>61</td>
<td>BCL1 Translocation, t(11;14)</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>62</td>
<td>BCL2 Translocation, t(14;18)²</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>63</td>
<td>BCR-ABL1 Non-Standard p230</td>
<td>No</td>
<td>81208</td>
</tr>
<tr>
<td></td>
<td>64</td>
<td>BCR-ABL1 Standard p210, p190²</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>65</td>
<td>BRAF Mutation Analysis</td>
<td>No</td>
<td>81210</td>
</tr>
<tr>
<td></td>
<td>66</td>
<td>BRCA2 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81216</td>
</tr>
<tr>
<td></td>
<td>67</td>
<td>BTK Inhibitor Acquired Resistance Panel</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>68</td>
<td>BTK Inhibitor Primary Susceptibility Panel</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>69</td>
<td>BTK Mutation Analysis²</td>
<td>No</td>
<td>81406</td>
</tr>
<tr>
<td></td>
<td>70</td>
<td>CALR Mutation Analysis</td>
<td>No</td>
<td>81219</td>
</tr>
<tr>
<td></td>
<td>71</td>
<td>CARD11 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>CBL Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>73</td>
<td>CD79B Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>74</td>
<td>CEBPA Mutation Analysis</td>
<td>No</td>
<td>81218</td>
</tr>
<tr>
<td></td>
<td>75</td>
<td>Chimerism/DNA Fingerprinting Analysis</td>
<td>No</td>
<td>81265 or 81266 or 81267 or 81268</td>
</tr>
<tr>
<td></td>
<td>76</td>
<td>CSF3R Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>77</td>
<td>CXCR4 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>78</td>
<td>DNMT3A Mutation Analysis</td>
<td>No</td>
<td>81403</td>
</tr>
<tr>
<td></td>
<td>79</td>
<td>EGFR Mutation Analysis</td>
<td>No</td>
<td>81235</td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>EGFR T790M Germline Mutation Analysis</td>
<td>No</td>
<td>81235</td>
</tr>
<tr>
<td></td>
<td>81</td>
<td>EGFRVIII Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>82</td>
<td>EPCAM Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81403</td>
</tr>
<tr>
<td></td>
<td>83</td>
<td>ETV6 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>84</td>
<td>ETV6-TEL-AML1 Translocation, t(12;21)</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>85</td>
<td>EZH2 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
</tbody>
</table>

¹CPT Code G0452 is not billed in NeoTYPE, NeoLAB  ²CPT code(s) updated - See “List of tests with updated CPT code(s)”

Note: Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients. The CPT codes provided here are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
# Medicare Billed - Molecular Tests (Continued)

<table>
<thead>
<tr>
<th>Category</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Panels &amp; Profiles</td>
<td>86</td>
<td>FLT3 Mutation Analysis²</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>87</td>
<td>GNAS Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>88</td>
<td>HOXB13 Genotyping</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>89</td>
<td>HRAS Mutation Analysis</td>
<td>No</td>
<td>81403</td>
</tr>
<tr>
<td></td>
<td>90</td>
<td>HSD3B1 Genotyping</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>91</td>
<td>IDH1 &amp; IDH2 Mutation Analysis²</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>92</td>
<td>IgH Clonality/MRD by NGS</td>
<td>No</td>
<td>81263</td>
</tr>
<tr>
<td></td>
<td>93</td>
<td>IgVH Mutation Analysis</td>
<td>No</td>
<td>81263</td>
</tr>
<tr>
<td></td>
<td>94</td>
<td>Inherited Bone Marrow Failure Panel²</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>95</td>
<td>inv(16), CBFB-MYH11 Translocation</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>96</td>
<td>JAK2 Exon 12-14 Mutation Analysis</td>
<td>No</td>
<td>JAK2 Exon 12-14 only: 81403x1. JAK2 V617F and Exon 12-14 run concurrently or by reflex: 81270x1, 81403x1</td>
</tr>
<tr>
<td></td>
<td>97</td>
<td>JAK2 V617F Mutation Analysis</td>
<td>No</td>
<td>JAK2 V617F only: 81270x1. JAK2 V617F and Exon 12-14 run concurrently or by reflex: 81270x1, 81403x1</td>
</tr>
<tr>
<td></td>
<td>98</td>
<td>KIT (c-KIT) Mutation Analysis</td>
<td>No</td>
<td>81272</td>
</tr>
<tr>
<td></td>
<td>99</td>
<td>KRAS Exon 4 Mutation Analysis</td>
<td>No</td>
<td>81276</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>KRAS Mutation Analysis</td>
<td>No</td>
<td>81275</td>
</tr>
<tr>
<td></td>
<td>101</td>
<td>MET (c-MET) Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>102</td>
<td>MET Exon 14 Deletion Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>103</td>
<td>MGMT Promoter Methylation Analysis</td>
<td>No</td>
<td>81287</td>
</tr>
<tr>
<td></td>
<td>104</td>
<td>Microsatellite Instability Analysis (MSI)</td>
<td>No</td>
<td>81301</td>
</tr>
<tr>
<td></td>
<td>105</td>
<td>MLH1 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81294</td>
</tr>
<tr>
<td></td>
<td>106</td>
<td>MLH1 Promoter Methylation Analysis</td>
<td>No</td>
<td>81288</td>
</tr>
<tr>
<td></td>
<td>107</td>
<td>MPL Mutation Analysis</td>
<td>No</td>
<td>81402</td>
</tr>
<tr>
<td></td>
<td>108</td>
<td>MPN Extended Reflex Panel²</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>109</td>
<td>MPN Standard Reflex Panel²</td>
<td>No</td>
<td>81270</td>
</tr>
<tr>
<td></td>
<td>110</td>
<td>MSH2 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81297</td>
</tr>
<tr>
<td></td>
<td>111</td>
<td>MSH6 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81298</td>
</tr>
</tbody>
</table>

¹ CPT Code G0452 is not billed in NeoTYPE, NeoLAB  
² CPT code(s) updated - See “List of tests with updated CPT code(s)”

Note: Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients.

The CPT codes provided here are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
### Medicare Billed - Molecular Tests (Continued)

<table>
<thead>
<tr>
<th>Category &amp; Profiles</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Panels &amp; Profiles</td>
<td>112</td>
<td>MYD88 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>113</td>
<td>NGS ALK, NTRK, RET, ROS1 Fusion Profile$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>114</td>
<td>NGS ALK, RET, ROS1 Fusion Profile$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>115</td>
<td>NGS Comprehensive Sarcoma Fusion Profile$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>116</td>
<td>NGS Ewing Sarcoma Fusion Profile</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>117</td>
<td>NGS Non-Ewing Sarcoma Fusion Profile$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>118</td>
<td>NGS Pediatric Sarcoma Fusion Profile$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>119</td>
<td>NGS Rhabdomyosarcoma Fusion Profile</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>120</td>
<td>NGS Thyroid Fusion Profile$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>121</td>
<td>NOTCH1 Mutation Analysis</td>
<td>No</td>
<td>81407</td>
</tr>
<tr>
<td></td>
<td>122</td>
<td>NPM1 MRD Mutation Analysis</td>
<td>No</td>
<td>81310</td>
</tr>
<tr>
<td></td>
<td>123</td>
<td>NPM1 Mutation Analysis</td>
<td>No</td>
<td>81310</td>
</tr>
<tr>
<td></td>
<td>124</td>
<td>NRAS Exon 4 Mutation Analysis</td>
<td>No</td>
<td>81403</td>
</tr>
<tr>
<td></td>
<td>125</td>
<td>NRAS Mutation Analysis</td>
<td>No</td>
<td>81311</td>
</tr>
<tr>
<td></td>
<td>126</td>
<td>Oncomine™ Dx Target Test</td>
<td>No</td>
<td>0022U</td>
</tr>
<tr>
<td></td>
<td>127</td>
<td>PDGFRα Mutation Analysis</td>
<td>No</td>
<td>81314</td>
</tr>
<tr>
<td></td>
<td>128</td>
<td>PIK3CA Mutation Analysis</td>
<td>No</td>
<td>81404</td>
</tr>
<tr>
<td></td>
<td>129</td>
<td>PLC-Gamma-2 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>130</td>
<td>PML-RARA Translocation, t(15;17)</td>
<td>No</td>
<td>81315</td>
</tr>
<tr>
<td></td>
<td>131</td>
<td>PMS2 Mutation &amp; Del/Dup Analysis</td>
<td>No</td>
<td>81317</td>
</tr>
<tr>
<td></td>
<td>132</td>
<td>PPM1D Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>133</td>
<td>PTEN Mutation Analysis</td>
<td>No</td>
<td>81321</td>
</tr>
<tr>
<td></td>
<td>134</td>
<td>PTPN11 Mutation Analysis</td>
<td>No</td>
<td>81406</td>
</tr>
<tr>
<td></td>
<td>135</td>
<td>RAS/RAF Panel$^2$</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>136</td>
<td>RHOA Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>137</td>
<td>RUNX1 Mutation Analysis$^2$</td>
<td>No</td>
<td>81334</td>
</tr>
<tr>
<td></td>
<td>138</td>
<td>RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21)</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td></td>
<td>139</td>
<td>SETBP1 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>140</td>
<td>SF3B1 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>141</td>
<td>SRSF2 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>142</td>
<td>STAT3 Mutation Analysis</td>
<td>No</td>
<td>81405</td>
</tr>
<tr>
<td></td>
<td>143</td>
<td>T-Cell Receptor Beta Gene Rearrangement</td>
<td>No</td>
<td>81340</td>
</tr>
<tr>
<td></td>
<td>144</td>
<td>T-Cell Receptor Gamma Gene Rearrangement</td>
<td>No</td>
<td>81342</td>
</tr>
</tbody>
</table>

$^1$ CPT Code G0452 is not billed in NeoTYPE, NeoLAB  
$^2$ CPT code(s) updated - See "List of tests with updated CPT code(s)"

**Note:** Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients.

The CPT codes provided here are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
## Medicare Billed - Molecular Tests (Continued)

<table>
<thead>
<tr>
<th>Category</th>
<th>No.</th>
<th>Test Name</th>
<th>NeoGenomics Bills Client</th>
<th>NeoGenomics Bills Medicare</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other Panels &amp; Profiles</td>
<td>145</td>
<td>TERT Promoter Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>146</td>
<td>TET2 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>147</td>
<td>TP53 Mutation Analysis</td>
<td>No</td>
<td>81405</td>
</tr>
<tr>
<td></td>
<td>148</td>
<td>TPMT Genotyping</td>
<td>No</td>
<td>81335</td>
</tr>
<tr>
<td></td>
<td>149</td>
<td>Tumor Mutation Burden</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>150</td>
<td>U2AF1 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>UGT1A1 Genotyping</td>
<td>No</td>
<td>81350</td>
</tr>
<tr>
<td></td>
<td>152</td>
<td>Universal Fusion/Expression Profile</td>
<td>No</td>
<td>81450</td>
</tr>
<tr>
<td></td>
<td>153</td>
<td>WT1 Mutation Analysis</td>
<td>No</td>
<td>81405</td>
</tr>
<tr>
<td></td>
<td>154</td>
<td>ZRSR2 Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
</tbody>
</table>

1 CPT Code G0452 is not billed in NeoTYPEs, NeoLAB
2 CPT code(s) updated - See "List of tests with updated CPT Code(s)"

**Note:** Many NeoTYPE Profiles include FISH and IHC whose codes are not listed above and will be billed to the clients.

The CPT codes provided here are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

### List of Tests with Updated CPT Code(s)

<table>
<thead>
<tr>
<th>Test No.</th>
<th>Test Name</th>
<th>March 2018</th>
<th>August 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>NeoLAB FLT3 Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81245, 81246</td>
</tr>
<tr>
<td>10</td>
<td>NeoLAB KRAS Mutation Analysis - Liquid Biopsy</td>
<td>No</td>
<td>81275, 81276</td>
</tr>
<tr>
<td>22</td>
<td>NeoTYPE Brain Tumor Profile</td>
<td>No</td>
<td>81445, G0452</td>
</tr>
<tr>
<td>31</td>
<td>NeoTYPE GI Predictive Profile</td>
<td>No</td>
<td>81210, 81403x2, 81275, 81276x2, 81311, 81301, G0452</td>
</tr>
<tr>
<td>60</td>
<td>B-Cell Gene Rearrangement</td>
<td>No</td>
<td>81261, 81264</td>
</tr>
<tr>
<td>62</td>
<td>BCL2 Translocation, t(14;18)</td>
<td>No</td>
<td>81402</td>
</tr>
<tr>
<td>64</td>
<td>BCR-ABL1 Standard p210, p190</td>
<td>No</td>
<td>81206, 81207</td>
</tr>
<tr>
<td>69</td>
<td>BTK Mutation Analysis</td>
<td>No</td>
<td>81479</td>
</tr>
<tr>
<td>86</td>
<td>FLT3 Mutation Analysis</td>
<td>No</td>
<td>81245</td>
</tr>
<tr>
<td>91</td>
<td>IDH1 &amp; IDH2 Mutation Analysis</td>
<td>No</td>
<td>81120, 81121</td>
</tr>
<tr>
<td>94</td>
<td>Inherited Bone Marrow Failure Panel</td>
<td>No</td>
<td>81455, 81479</td>
</tr>
<tr>
<td>100</td>
<td>KRAS Mutation Analysis</td>
<td>No</td>
<td>81275, 81276</td>
</tr>
<tr>
<td>Test No.</td>
<td>Test Name</td>
<td>March 2018</td>
<td>August 2018</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------</td>
<td>----------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NeoGenomics Bills Client</td>
<td>NeoGenomics Bills Medicare</td>
</tr>
<tr>
<td>108</td>
<td>MPN Extended Reflex Panel</td>
<td>No</td>
<td>81219, 81270, 81402, 81403</td>
</tr>
<tr>
<td>109</td>
<td>MPN Standard Reflex Panel</td>
<td>No</td>
<td>81270, 81402, 81403</td>
</tr>
<tr>
<td>113</td>
<td>NGS ALK, NTRK, RET, ROS1 Fusion Profile</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td>114</td>
<td>NGS ALK, RET, ROS1 Fusion Profile</td>
<td>No</td>
<td>81404, 81479x2</td>
</tr>
<tr>
<td>115</td>
<td>NGS Comprehensive Sarcoma Fusion Profile</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td>117</td>
<td>NGS Non-Ewing Sarcoma Fusion Profile</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td>118</td>
<td>NGS Pediatric Sarcoma Fusion Profile</td>
<td>No</td>
<td>81445</td>
</tr>
<tr>
<td>120</td>
<td>NGS Thyroid Fusion Profile</td>
<td>No</td>
<td>81405, 81479x2</td>
</tr>
<tr>
<td>135</td>
<td>RAS/RAF Panel</td>
<td>No</td>
<td>81311x1, 81404x1, 81405x1, 81406x1</td>
</tr>
<tr>
<td>137</td>
<td>RUNX1 Mutation Analysis</td>
<td>No</td>
<td>81401</td>
</tr>
<tr>
<td>152</td>
<td>Universal Fusion/Expression Profile</td>
<td>No</td>
<td>81455</td>
</tr>
</tbody>
</table>